Ginkgo Bioworks Holdings, Inc.

NYSE:DNA

Biotechnology

Healthcare
$8.44 +3.04%

+$0.26 today

Market cap
$547.12M
Beta
1.80
P/E (TTM)
-1.7
EPS (TTM)
-$5.11
52W Low $5.37High $17.58

Volume 2.36M

Average 1.24M

DNA Cost of Revenue

Direct costs of producing the goods and services sold, such as materials, manufacturing, and service delivery.

Ginkgo Bioworks Holdings, Inc.NYSE: DNA

Cost of Revenue · Q1 FY2026 · quarter ended Mar 2026

Cost of revenue growth accelerates

Q1 FY2026 cost of revenue of $15.9M rose 32.0% year over year, ahead of the -22.1% change in trailing-twelve-month cost of revenue. Over 3 fiscal years it compounded at -46.4% a year.

Context

  • Cost of revenue amounted to 18.5% of revenue in FY2025, up 1.5 pp from a year earlier.
  • Cost of revenue increased in 0 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +32.0% holds above the trailing-twelve-month pace of -22.1%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$15.9M+295.1% QoQ
Last fiscal yearDec 2025
$31.52M-18.2% YoY
LTMMar 2026
$35.37M-22.1% YoY
Cost of Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+32.0%——
1 year-18.2%——
3-year CAGR-46.4%——
5-year CAGR——
10-year CAGR——

Cost of Revenue history

USD · from the income statement

Latest · FY2025
31.52M USD
Year-over-year change
-18.2%
4-year CAGR
-29.8%

Cost of Revenue vs competitors

How DNA compares with its peers on the latest reported figures

  • Peers report in different currencies, so cost of revenue is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -22.1% is the 6th highest of 8, against a peer median of +0.9%.
  • Cost of revenue amounts to 25.0% of revenue for DNA, versus a peer median of 56.1%.
DNA Competitors
Cost of Revenue for DNA and competitors
Company Period LTM YoY 3-year CAGR% of revenue
IOVAIovance Biotherapeutics, Inc.LTM Sep 2026$177.23M USD+0.9%—46.8%
MRVIMaravai LifeSciences Holdings, Inc.LTM Jun 2026$136.53M USD-10.8%-3.4%65.4%
VALNValneva SELTM Mar 2026€110.28M EUR+10.9%-30.9%70.5%
DNAGinkgo Bioworks Holdings, Inc.LTM Mar 2026$35.37M USD-22.1%-46.4%25.0%
MGTXMeiraGTx Holdings plcLTM Mar 2026$6.67M USD-73.5%—8.4%
ARVNArvinas, Inc.LTM Mar 2026$2.3M USD+35.3%—2.6%
REPLReplimune Group, Inc.LTM Dec 2025$848K USD———
MBXMBX Biosciences, Inc. Common StockLTM Sep 2026$124K USD+24.0%——
AVBPArriVent BioPharma, Inc. Common StockLTM Mar 2026$0 USD———
VIRVir Biotechnology, Inc.LTM Mar 2026-$114.78M USD-122.6%-73.4%175.2%
Peer median (excluding DNA) —+0.9%-30.9%56.1%

Competitors are the stored peer set for DNA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue313.84M477.71M251.46M227.04M170.16M
Cost of Revenue129.69M204.22M54.01M38.55M31.52M
Gross Profit184.15M273.49M197.45M188.49M138.63M
Gross Margin58.7%57.3%78.5%83.0%81.5%
Research & Development1.15B1.05B580.62M424.06M243.77M
Selling, General & Admin862.95M1.43B385.03M246.16M183.29M
Operating Expenses2.01B2.48B1.06B748.25M453.91M
Depreciation & Amortization29.08M61.63M71.55M63.02M58.99M
EBITDA(1.81B)(2.06B)(821.29M)(484.39M)(254.61M)
EBITDA Margin-575.7%-431.2%-326.6%-213.3%-149.6%
Operating Income(1.83B)(2.21B)(864.41M)(559.76M)(315.28M)
Operating Margin-582.6%-462.4%-343.8%-246.5%-185.3%
Interest Income837K20.26M57.22M38.61M22.62M
Interest Expense2.37M106K93K94K0
Other Income / Expenses(9.66M)87.55M(28.53M)12.25M1.68M
Income Before Tax(1.84B)(2.12B)(892.94M)(547.51M)(313.6M)
Pre-Tax Margin-585.7%-444.1%-355.1%-241.1%-184.3%
Income Tax Expense(1.48M)(15.03M)(71K)(479K)(837K)
Net Income(1.83B)(2.1B)(892.87M)(547.03M)(312.76M)
Net Margin-583.1%-440.6%-355.1%-240.9%-183.8%
EPS (Basic)(53.83)(50.15)(18.37)(10.54)(5.64)
EPS (Diluted)(55.53)(50.20)(18.40)(10.54)(5.64)
Weighted Avg Shares32.95M41.93M48.53M51.89M55.46M
Weighted Avg Shares (Diluted)34.01M42M48.61M51.89M55.46M

Ginkgo Bioworks Holdings, Inc.

NYSE:DNA

Intrinsic Alpha fair value

Locked

Current Price

$8.44

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.